MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes

Nature Communications

Volumn 8, Issue , 2017, Pages

  Lopez, Juan Pablo ^a   Fiori, Laura M ^a   Cruceanu, Cristiana ^a   Lin, Rixing ^a   Labonte, Benoit ^b   Cates, Hannah M ^b   Heller, Elizabeth A ^b   Vialou, Vincent ^b   Ku, Stacy M ^b   Gerald, Christophe ^b   Han, Ming Hu ^b   Foster, Jane ^c   Frey, Benicio N ^d   Soares, Claudio N ^e,f   Müller, Daniel J ^c,g   Farzan, Faranak ^c,g,h   Leri, Francesco ⁱ   Macqueen, Glenda M ^j   Feilotter, Harriet ^f   Tyryshkin, Kathrin ^f   Evans, Kenneth R ^f,k   Giacobbe, Peter ^c   Blier, Pierre ^l   Lam, Raymond W ^m   Milev, Roumen ^f   Parikh, Sagar V ⁿ   Rotzinger, Susan ^c   Strother, Steven C ^o   Lewis, Cathryn M ^p   Aitchison, Katherine J ^q,r   Wittenberg, Gayle M ^s   Mechawar, Naguib ^a   Nestler, Eric J ^b   Uher, Rudolf ^p,r   Kennedy, Sidney H ^c   Turecki, Gustavo ^a   more..

^a MCGILL UNIVERSITY   (Canada)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

^g CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^h School of Engineering Science   (Canada)

ⁱ UNIVERSITY OF GUELPH   (Canada)

^j UNIVERSITY OF CALGARY   (Canada)

^k Indoc Research   (Canada)

^l UNIVERSITY OF OTTAWA   (Canada)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁿ UNIVERSITY OF MICHIGAN   (United States)

^o ROTMAN RESEARCH INSTITUTE   (Canada)

^p KING'S COLLEGE LONDON   (United Kingdom)

^q UNIVERSITY OF ALBERTA   (Canada)

^r DALHOUSIE UNIVERSITY   (Canada)

^s Janssen Research and Development LLC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; DULOXETINE; ESCITALOPRAM; IMIPRAMINE; MICRORNA; MICRORNA 1180; MICRORNA 146A; MICRORNA 146B; MICRORNA 2110; MICRORNA 215; MICRORNA 24; MICRORNA 3074; MICRORNA 30E; MICRORNA 3173; MICRORNA 3184; MICRORNA 324; MICRORNA 3605; MICRORNA 361; MICRORNA 423; MICRORNA 425; MICRORNA 503; MICRORNA 636; MICRORNA 6511A; MICRORNA 6750; MICRORNA 6881; MITOGEN ACTIVATED PROTEIN KINASE; NORTRIPTYLINE; UNCLASSIFIED DRUG; MIRN146 MICRORNA, HUMAN; MIRN146 MICRORNA, MOUSE; MIRN24 MICRORNA, HUMAN; MIRN24 MICRORNA, MOUSE; MIRN425 MICRORNA, HUMAN;

BRAIN; DISABILITY; DISEASE TREATMENT; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC MARKER; MENTAL HEALTH;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; ELECTROCONVULSIVE THERAPY; EMBRYO; FEMALE; GENE EXPRESSION; GENETIC MARKER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOUSE; NONHUMAN; PHARMACOGENOMICS; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RNA SEQUENCE; TREATMENT RESPONSE; WNT SIGNALING PATHWAY; ADULT; AGED; ANIMAL; BIOLOGY; BRAIN; C57BL MOUSE; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; MAPK SIGNALING; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; WNT SIGNALING; YOUNG ADULT;

ANIMALIA;

ADULT; AGED; ANIMALS; ANTIDEPRESSIVE AGENTS; BIOMARKERS; BRAIN; COMPUTATIONAL BIOLOGY; DEPRESSIVE DISORDER, MAJOR; DULOXETINE HYDROCHLORIDE; FEMALE; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICRORNAS; MIDDLE AGED; WNT SIGNALING PATHWAY; YOUNG ADULT;

EID: 85019925601     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms15497     Document Type: Article

References (50)

1. Schmidt, H. D., Shelton, R. C. & Duman, R. S. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 36, 2375-2394 (2011).
2. Banthin, J. S. & Miller, G. E. Trends in prescription drug expenditures by Medicaid enrollees. Med. Care 44, I27-I35 (2006).
3. Chen, Y. et al. Utilization, price, and spending trends for antidepressants in the US Medicaid Program. Res. Social Adm. Pharm. 4, 244-257 (2008).
4. Esteller, M. Non-coding RNAs in human disease. Nat. Rev. Genet. 12, 861-874 (2011).
5. Lopez, J. P. et al. Biomarker discovery: quantification of microRNAs and other small non-coding RNAs using next generation sequencing. BMC Med. Genomics 8, 35 (2015).
6. He, L. & Hannon, G. J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genetics 5, 522-531 (2004).
7. Qureshi, I. A. & Mehler, M. F. Emerging roles of non-coding RNAs in brain evolution, development, plasticity and disease. Nat. Rev. Neurosci. 13, 528-541 (2012).
8. Baudry, A., Mouillet-Richard, S., Schneider, B., Launay, J. M. & Kellermann, O. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 329, 1537-1541 (2010).
9. Launay, J. M., Mouillet-Richard, S., Baudry, A., Pietri, M. & Kellermann, O. Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16. Transl. Psychiatry 1, e56 (2011).
10. Issler, O. et al. MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotonergic activity. Neuron 83, 344-360 (2014).
11. Dias, C. et al. beta-catenin mediates stress resilience through Dicer1/microRNA regulation. Nature 516, 51-55 (2014).
12. Lopez, J. P. et al. miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment. Nat. Med. 20, 764-768 (2014).
13. Kennedy, S. H., Andersen, H. F. & Lam, R. W. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J. Psychiatry Neurosci. 31, 122-131 (2006).
14. Kennedy, S. H. et al. The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. Curr. Pharm. Des. 18, 5976-5989 (2012).
15. Kennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B. & Ravindran, A. V. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. J. Affect. Disord. 117, S1-S2 (2009).
16. Pecina, M. et al. Association between placebo-activated neural systems and antidepressant responses: neurochemistry of placebo effects in major depression. JAMA Psychiatry 72, 1087-1094 (2015).
17. Pecina, M. & Zubieta, J. K. Molecular mechanisms of placebo responses in humans. Mol. Psychiatry 20, 416-423 (2015).
18. Uher, R. et al. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br. J. Psychiatry 194, 252-259 (2009).
19. Lam, R. W. et al. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry 16, 105 (2016).
20. Krishnan, V. et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 131, 391-404 (2007).
21. Huang, da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
22. Vlachos, I. S. et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. 43, W460-W466 (2015).
23. Duman, R. S., Li, N., Liu, R. J., Duric, V. & Aghajanian, G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62, 35-41 (2012).
24. Perroud, N. et al. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology 34, 2517-2528 (2009).
25. Perroud, N. et al. Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics J. 12, 68-77 (2012).
26. Duric, V. & Duman, R. S. Depression and treatment response: dynamic interplay of signaling pathways and altered neural processes. Cell. Mol. Life Sci. 70, 39-53 (2013).
27. Yi, Z. et al. Blood-based gene expression profiles models for classification of subsyndromal symptomatic depression and major depressive disorder. PLoS ONE 7, e31283 (2012).
28. Hepgul, N., Cattaneo, A., Zunszain, P. A. & Pariante, C. M. Depression pathogenesis and treatment: what can we learn from blood mRNA expression? BMC Med. 11, 28 (2013).
29. Jansen, R. et al. Gene expression in major depressive disorder. Mol. Psychiatry 21, 444 (2016).
30. Xu, F. et al. Differential co-expression and regulation analyses reveal different mechanisms underlying major depressive disorder and subsyndromal symptomatic depression. BMC Bioinformatics 16, 112 (2015).
31. Chao, M. V. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat. Rev. Neurosci. 4, 299-309 (2003).
32. Lopez, J. P. et al. Epigenetic regulation of BDNF expression according to antidepressant response. Mol. Psychiatry 18, 398-399 (2012).
33. Turner, C. A., Akil, H., Watson, S. J. & Evans, S. J. The fibroblast growth factor system and mood disorders. Biol. Psychiatry 59, 1128-1135 (2006).
34. Illumina. Illumina CASAVA 1.8 http://support.illumina.com/content/dam/illumina-support/documents/myillumina/33d66b02-53b5-4f4d-9d8bf94237c7e44d/casava-qrg-15011197b.pdf (2011).
35. Song, L., Florea, L. & Langmead, B. Lighter: fast and memory-efficient sequencing error correction without counting. Genome Biol. 15, 509 (2014).
36. Kent, W. J. et al. The human genome browser at UCSC. Genome Res. 12, 996-1006 (2002).
37. Chen, C. J. et al. ncPRO-seq: a tool for annotation and profiling of ncRNAs in sRNA-seq data. Bioinformatics 28, 3147-3149 (2012).
38. Kozomara, A. & Griffiths-Jones, S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39, D152-D157 (2011).
39. Kozomara, A. & Griffiths-Jones, S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 42, D68-D73 (2014).
40. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
41. Li, J. & Tibshirani, R. Finding consistent patterns: a nonparametric approach for identifying differential expression in RNA-Seq data. Stat. Methods Med. Res. 22, 519-536 (2013).
42. Dweep, H. & Gretz, N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat. Methods 12, 697 (2015).
43. Wong, N. & Wang, X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 43, D146-D152 (2015).
44. Betel, D., Koppal, A., Agius, P., Sander, C. & Leslie, C. Comprehensive modeling of microRNA targets predicts functional non-conserved and noncanonical sites. Genome Biol. 11, R90 (2010).
45. Miranda, K. C. et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 126, 1203-1217 (2006).
46. Kruger, J. & Rehmsmeier, M. RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res. 34, W451-W454 (2006).
47. Agarwal, V., Bell, G. W., Nam, J. W. & Bartel, D. P. Predicting effective microRNA target sites in mammalian mRNAs. eLife 4, e05005 (2015).
48. Paraskevopoulou, M. D. et al. DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res. 41, W169-W173 (2013).
49. Golden, S. A., Covington, 3rd H. E., Berton, O. & Russo, S. J. A standardized protocol for repeated social defeat stress in mice. Nat. Protoc. 6, 1183-1191 (2011).
50. Berton, O. & Nestler, E. J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 7, 137-151 (2006).